Actively Recruiting
Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19
Led by Instituto Nacional de Rehabilitacion · Updated on 2025-03-07
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying people who have long COVID, focusing on neurological symptoms like depression, anxiety, and fatigue. The study aims to analyze certain blood components, including microRNAs and vitamin B12, to better understand the body changes after COVID-19. This could help develop improved therapies and diagnostic methods tailored to these symptoms. The study hypothesizes that specific microRNAs (miR-21, -146a, and -155) will be overexpressed and that there will be vitamin B12 deficiency in those affected. The study compares two groups: individuals with neurological symptoms of depression, anxiety, and fatigue three months after acute COVID-19 infection, and a control group without these symptoms twelve weeks after infection. Blood samples will be taken from both groups to measure levels of microRNAs and vitamin B12. Researchers will link these blood markers with scores from tests that evaluate depression, anxiety, and fatigue symptoms. Participants will undergo blood collection and complete questionnaires assessing their neurological symptoms. The main measurements include changes in microRNA expression and vitamin B12 levels immediately after blood extraction. These will be correlated with symptom scores to understand the relationship. The study also monitors participants for safety and will last until July 2025, with no additional treatment given as it is observational.
CONDITIONS
Brief Title
Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing.
- Presence of neurological symptoms of depression, anxiety, and fatigue associated with COVID-19 lasting at least three months from the first day of acute infection symptoms.
- Age between 18 and 65 years.
You will not qualify if you...
- Subjects who have had symptoms of acute COVID-19 infection within the last twelve weeks.
- Subjects with pre-existing neurological disorders diagnosed before COVID-19 infection.
- Subjects who have not received at least two doses of COVID-19 vaccine, or whose last vaccine dose was less than three months ago.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants provide blood samples to evaluate microRNAs and vitamin B12 expression related to neurological symptoms.
1 visit (in-person)
Duration - Immediate after sample collection
Participants are observed to link biomarker expression with symptoms of depression, anxiety, and fatigue.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Instituto Nacional de Rehabilitación
Mexico City, Mexico City, Mexico, 14389
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here